Centre for Cell Signalling and Molecular Genetics

Key Publications

PROFILE

UK Science and Technology, Public Services Review 6. (2012). Breathing Power into the Cell. pg 20-21.

http://edition.pagesuite-professional.co.uk/Launch.aspx?EID=68b13021-1bc2-4391-9fe9-19ddc694d08b

SELECTED PUBLICATIONS

Baker LC, Boult JK, Walker-Samuel S, Chung YL, Jamin Y, Ashcroft M, Robinson SP. (2012) The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br J Cancer. 106(10):1638-47.

Yang J, Staples O, Thomas LW, Briston T, Robson M, Poon E, Simões ML, El-Emir E, Buffa FM, Ahmed A, Annear NP, Shukla D, Pedley BR, Maxwell PH, Harris AL, Ashcroft M. (2012) Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. J Clin Invest. 122(2):600-11.

Wilson GK, Brimacombe CL, Rowe IA, Reynolds GM, Fletcher NF, Stamataki Z, Bhogal RH, Simões ML, Ashcroft M, Afford SC, Mitry RR, Dhawan A, Mee CJ, Hübscher SG, Balfe P, McKeating JA. (2012) A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. J Hepatol. 56(4):803-9.

Briston T, Yang J, Ashcroft M. (2011) HIF-1α localization with mitochondria: a new role for an old favorite? Cell Cycle. 10(23):4170-1.

Harten SK, Esteban MA, Shukla D, Ashcroft M, Maxwell PH. (2011) Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells. Mol Cancer. 10:89.

Ahmed A, Yang J, Maya-Mendoza A, Jackson DA, Ashcroft M. (2011) Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1. Cell Death Dis. 2:e160.

Khan MN, Bhattacharyya T, Andrikopoulos P, Esteban MA, Barod R, Connor T, Ashcroft M, Maxwell PH, Kiriakidis S. (2011) Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis. Br J Cancer. 104(7):1151-9.

Ahmed A, Ashcroft M. TRP-ing off the p53 apoptotic switch. (2010) Pigment Cell Melanoma Res. (5):581-2.

Palmer CD, Rahman FZ, Sewell GW, Ahmed A, Ashcroft M, Bloom SL, Segal AW, Smith AM. (2009) Diminished Macrophage Apoptosis and Reactive Oxygen Species Generation after Phorbol Ester Stimulation in Crohn’s Disease. PLoS One. 4(11):e7787.

Harten S, Ashcroft M, Maxwell PH. (2009) Prolyl hydroxyase inhibitors: a route to HIF activation and neuroprotection. Antioxidants and Redox Signaling (4):459-80.

Poon P and Ashcroft M. (2009) Targeting the hypoxia inducible factor (HIF) pathway in cancer. Expert Review in Molecular Medicine. Aug 27, 11:e26.

Maxwell PH and Ashcroft M. (2009) Angiogenic Cancer Therapy. Brit J Cancer 100: 1515-1516.

Yang J, Poon E, Ahmed A and Ashcroft M. (2009) Activation of a unique p53-dependent DNA damage response. Cell Cycle 8(10):1630-2.

Yang J, Ahmed A, Poon E, Perusinghe N, de Haven Brandon A, Box G, Valenti M, Eccles S and Ashcroft M. (2009) Small molecule activation of p53 blocks HIF-1α and VEGF 1 expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Biol Cell (8):2243-53.

Alam H, Weck J, Maizels E, Park Y, Lee EJ, Ashcroft M, Hunzicher-Dunn M. (2009) Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone. Endocrinology 150(2):915-28.

Carroll V and Ashcroft M. (2008) Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Research 15;68(2):545-52.

Sutton KM, Hayat S, Chau NM, Cook S, Pouyssegur J, Ahmed A, Perusinghe N, Le Floch R, Yang J and Ashcroft M. (2007) Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene 26(27):3920-9.

Carroll V and Ashcroft M. (2006) Role of HIF-1α versus HIF-2α in the regulation of HIF target genes in response to hypoxia, IGF-1, or loss of VHL function: Implications for targeting the HIF Pathway. Cancer Research 66(12): 6264-6270.

Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE and Keith WN. (2006) Hypoxia regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 25(1):61-9.

Chau N-M, Rogers P, Aherne W, Collins I, McDonald E, Workman P, Ashcroft M. (2005) Identification of novel small molecule inhibitors of hypoxia inducible factor-1 that differentially block hypoxia inducible factor-1 activity and hypoxia inducible factor-1αinduction in response to hypoxia stress and growth factors. Cancer Research 65 (11): 4918-4928.

Carroll VA, Ashcroft,M. (2005). Targeting the molecular basis for tumour hypoxia. Expert Rev Mol Med 7(6), 1-16

Bárdos JI and Ashcroft M. (2005) Negative and Positive Regulation of HIF-1: A Complex Network. Biochim Biophys Acta 1755(2):107-20.Carroll V and Ashcroft M. (2005) Targeting the molecular basis for tumour hypoxia. Expert Review in Molecular Medicine 7(6):1-16.

Bárdos JI, Chau N-M, Ashcroft M. (2004) Growth factor-mediated induction of HDM2 positively regulates HIF-1α expression. Mol Cell Biol 24 (7): 2905-2914.

Kaufman B, Scharf O, Arbeit J, Ashcroft M, Brown JM, Bruick RK, Chapman JD, Evans SM, Giaccia AJ, Harris AL, Huang E, Johnson R, Kaelin W Jr, Koch CJ, Maxwell P, Mitchell J, Neckers L, Powis G, Rajendran J, Semenza GL, Simons J, Storkebaum E, Welch MJ, Whitelaw M, Melillo G, Ivy SP. (2004) Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Research 64(9):3350-6.

Bárdos JI and Ashcroft M. (2004) Regulation of HIF-1 activity and function. BioEssays 26: 262-269.

Chau N-M and Ashcroft M. (2004) Akt2: A role in breast cancer metastasis. Breast Cancer Res 6 (1): 55-57.

Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber O, MacRae EJ, Vousden KH. (2002) Phosphorylation of HDM2 by Akt. Oncogene, 21: 1955-1962.

Ashcroft M, Yoichi T, Vousden KH. (2000) Stress Signals Utilize Multiple Pathways to Stabilize p53. Mol Cell Biol 20(9):3224-3233.

Lohrum MAE, Ashcroft M, Kubbutat MHG, Vousden KH. (2000) Identification of a Cryptic Nucleolar Localization Signal in MDM2. Nature Cell Biol 2:179-181.

Lohrum MAE, Ashcroft M, Kubbutat MHG, Vousden KH. (2000) Contribution of two independent MDM2 binding domains in p14ARF to p53 stabilization. Current Biol 10:539-542.

Nakano K, Balint E, Ashcroft M, Vousden KH. (2000) A Ribonucleotide Reductase Gene is a Transcriptional Target of p53 and p73. Oncogene 19:4283-4289.

Pise-Masison CA, Mahieux R, Jiang H, Hoffman A, Ashcroft M, Radonovich M, Duvall J, Brady JN. (2000) Inactivation of p53 by HTLV-I Tax requires activation of RelA/NFkB pathway and is dependent on p53 phosphorylation. Mol Cell Biol 20(10):3377-3386.

Ashcroft M, Kubbutat MHG, Vousden KH. (1999a) Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 19(3): 1751-8.

Ashcroft M, and Vousden KH. (1999b) The Regulation of p53 Stability. Oncogene 18(53):7637-7644.

Ashcroft M, Stephens RM, Hallberg B, Downward J, Kaplan DR. (1999c) Role of PI-3 kinase in nerve growth factor-mediated survival of PC12 cells. Oncogene 12:18(32):4586-97.

Hallberg B, Ashcroft M, Kaplan DR, Downward J. (1998) Role of PI-3 kinase in signalling pathways activated by Nerve Growth Factor. Oncogene 13:17(6):691-7.

Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH. (1998) Regulation of Mdm2-directed degradation by the C-terminus of p53. Mol Cell Biol 18(10): 5690-8.

Allen SJ, Dawbarn D, Eckford SD, Wilcock GK, Ashcroft M, Colebrook SM, Feeney R, MacGowan SH. (1994) Cloning of the non-catalytic form of human trkB and distribution of mRNA for trkB in human brain. Neuroscience: 60 (3):825-834.